Hoth Free Cash Flow Per Share vs Capex To Depreciation Analysis

HOTH Stock

USD 1.19 0.02 1.71%

Hoth Therapeutics financial indicator trend analysis is much more than just examining Hoth Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hoth Therapeutics is a good investment. Please check the relationship between Hoth Therapeutics Free Cash Flow Per Share and its Capex To Depreciation accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.

Free Cash Flow Per Share vs Capex To Depreciation

Free Cash Flow Per Share vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hoth Therapeutics Free Cash Flow Per Share account and Capex To Depreciation. At this time, the significance of the direction appears to have no relationship.

The correlation between Hoth Therapeutics' Free Cash Flow Per Share and Capex To Depreciation is 0.07. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Hoth Therapeutics, assuming nothing else is changed. The correlation between historical values of Hoth Therapeutics' Free Cash Flow Per Share and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of Hoth Therapeutics are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Free Cash Flow Per Share i.e., Hoth Therapeutics' Free Cash Flow Per Share and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

0.07

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most indicators from Hoth Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hoth Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.As of now, Hoth Therapeutics' Enterprise Value Over EBITDA is increasing as compared to previous years. The Hoth Therapeutics' current Enterprise Value Multiple is estimated to increase to 0.59, while Selling General Administrative is projected to decrease to 4,002.

Hoth Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Retained Earnings Total Equity
Total Assets		0.88	0.8	1.0	0.92	0.45	-0.93	-0.88	0.44	0.97	0.64	0.0	1.0	0.92	-0.64	0.32	0.9	0.94	0.82	1.0	0.45	1.0	1.0	0.54	-0.81	-0.9
Other Current Liab	0.88		0.94	0.84	0.9	0.45	-0.88	-0.92	0.58	0.91	0.35	-0.08	0.88	0.85	-0.69	0.27	0.84	0.96	0.92	0.84	0.45	0.89	0.85	0.19	-0.79	-0.83
Total Current Liabilities	0.8	0.94		0.74	0.83	0.26	-0.78	-0.85	0.81	0.8	0.36	0.16	0.8	0.81	-0.76	0.49	0.81	0.87	0.99	0.74	0.26	0.8	0.75	0.21	-0.82	-0.84
Total Stockholder Equity	1.0	0.84	0.74		0.9	0.47	-0.92	-0.86	0.37	0.97	0.65	-0.02	1.0	0.9	-0.6	0.28	0.88	0.93	0.76	1.0	0.47	0.99	1.0	0.56	-0.78	-0.87
Net Tangible Assets	0.92	0.9	0.83	0.9		0.67	-0.99	-0.99	0.39	0.92	0.42	-0.06	0.92	0.83	-0.61	0.16	0.94	0.94	0.83	0.9	0.67	0.92	0.91	0.24	-0.75	-0.9
Property Plant And Equipment Net	0.45	0.45	0.26	0.47	0.67		-0.69	-0.69	-0.29	0.52	-0.05	-0.2	0.45	0.36	-0.22	-0.37	0.57	0.53	0.22	0.47	1.0	0.46	0.47	-0.22	-0.31	-0.41
Net Debt	-0.93	-0.88	-0.78	-0.92	-0.99	-0.69		0.96	-0.32	-0.95	-0.4	0.12	-0.94	-0.8	0.55	-0.09	-0.89	-0.92	-0.78	-0.92	-0.69	-0.94	-0.93	-0.29	0.7	0.84
Retained Earnings	-0.88	-0.92	-0.85	-0.86	-0.99	-0.69	0.96		-0.41	-0.9	-0.37	-0.01	-0.88	-0.85	0.66	-0.19	-0.94	-0.95	-0.84	-0.86	-0.69	-0.89	-0.87	-0.15	0.8	0.9
Accounts Payable	0.44	0.58	0.81	0.37	0.39	-0.29	-0.32	-0.41		0.41	0.31	0.48	0.44	0.56	-0.61	0.76	0.44	0.5	0.8	0.37	-0.29	0.44	0.38	0.24	-0.63	-0.55
Cash	0.97	0.91	0.8	0.97	0.92	0.52	-0.95	-0.9	0.41		0.45	-0.09	0.98	0.86	-0.53	0.18	0.84	0.96	0.79	0.97	0.52	0.98	0.97	0.37	-0.73	-0.82
Non Current Assets Total	0.64	0.35	0.36	0.65	0.42	-0.05	-0.4	-0.37	0.31	0.45		0.34	0.61	0.7	-0.65	0.67	0.64	0.46	0.47	0.65	-0.05	0.61	0.63	0.87	-0.7	-0.71
Non Currrent Assets Other	0.0	-0.08	0.16	-0.02	-0.06	-0.2	0.12	-0.01	0.48	-0.09	0.34		-0.02	0.27	-0.44	0.8	0.18	0.04	0.14	-0.02	-0.2	-0.01	-0.03	0.2	-0.45	-0.23
Cash And Short Term Investments	1.0	0.88	0.8	1.0	0.92	0.45	-0.94	-0.88	0.44	0.98	0.61	-0.02		0.91	-0.61	0.3	0.89	0.95	0.81	1.0	0.45	1.0	1.0	0.51	-0.8	-0.89
Common Stock Total Equity	0.92	0.85	0.81	0.9	0.83	0.36	-0.8	-0.85	0.56	0.86	0.7	0.27	0.91		-0.77	0.55	0.93	0.93	0.84	0.9	0.36	0.91	0.9	0.45	-0.94	-0.95
Common Stock Shares Outstanding	-0.64	-0.69	-0.76	-0.6	-0.61	-0.22	0.55	0.66	-0.61	-0.53	-0.65	-0.44	-0.61	-0.77		-0.73	-0.79	-0.66	-0.77	-0.6	-0.22	-0.63	-0.59	-0.44	0.93	0.8
Non Current Liabilities Total	0.32	0.27	0.49	0.28	0.16	-0.37	-0.09	-0.19	0.76	0.18	0.67	0.8	0.3	0.55	-0.73		0.41	0.3	0.53	0.28	-0.37	0.31	0.27	0.54	-0.71	-0.53
Capital Surpluse	0.9	0.84	0.81	0.88	0.94	0.57	-0.89	-0.94	0.44	0.84	0.64	0.18	0.89	0.93	-0.79	0.41		0.91	0.84	0.88	0.57	0.89	0.88	0.36	-0.9	-0.98
Other Stockholder Equity	0.94	0.96	0.87	0.93	0.94	0.53	-0.92	-0.95	0.5	0.96	0.46	0.04	0.95	0.93	-0.66	0.3	0.91		0.87	0.93	0.53	0.95	0.93	0.26	-0.84	-0.9
Total Liab	0.82	0.92	0.99	0.76	0.83	0.22	-0.78	-0.84	0.8	0.79	0.47	0.14	0.81	0.84	-0.77	0.53	0.84	0.87		0.76	0.22	0.82	0.77	0.29	-0.84	-0.88
Net Invested Capital	1.0	0.84	0.74	1.0	0.9	0.47	-0.92	-0.86	0.37	0.97	0.65	-0.02	1.0	0.9	-0.6	0.28	0.88	0.93	0.76		0.47	0.99	1.0	0.56	-0.78	-0.87
Property Plant And Equipment Gross	0.45	0.45	0.26	0.47	0.67	1.0	-0.69	-0.69	-0.29	0.52	-0.05	-0.2	0.45	0.36	-0.22	-0.37	0.57	0.53	0.22	0.47		0.46	0.47	-0.22	-0.31	-0.41
Total Current Assets	1.0	0.89	0.8	0.99	0.92	0.46	-0.94	-0.89	0.44	0.98	0.61	-0.01	1.0	0.91	-0.63	0.31	0.89	0.95	0.82	0.99	0.46		1.0	0.52	-0.81	-0.89
Net Working Capital	1.0	0.85	0.75	1.0	0.91	0.47	-0.93	-0.87	0.38	0.97	0.63	-0.03	1.0	0.9	-0.59	0.27	0.88	0.93	0.77	1.0	0.47	1.0		0.54	-0.78	-0.87
Common Stock	0.54	0.19	0.21	0.56	0.24	-0.22	-0.29	-0.15	0.24	0.37	0.87	0.2	0.51	0.45	-0.44	0.54	0.36	0.26	0.29	0.56	-0.22	0.52	0.54		-0.46	-0.45
Property Plant Equipment	-0.81	-0.79	-0.82	-0.78	-0.75	-0.31	0.7	0.8	-0.63	-0.73	-0.7	-0.45	-0.8	-0.94	0.93	-0.71	-0.9	-0.84	-0.84	-0.78	-0.31	-0.81	-0.78	-0.46		0.92
Retained Earnings Total Equity	-0.9	-0.83	-0.84	-0.87	-0.9	-0.41	0.84	0.9	-0.55	-0.82	-0.71	-0.23	-0.89	-0.95	0.8	-0.53	-0.98	-0.9	-0.88	-0.87	-0.41	-0.89	-0.87	-0.45	0.92

Click cells to compare fundamentals

Hoth Therapeutics Account Relationship Matchups

Hoth Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.8M	5.2M	11.0M	6.8M	9.5M	5.8M
Other Current Liab	36.2K	182.7K	506.8K	692.7K	614.2K	352.1K
Total Current Liabilities	440.1K	312.1K	867.8K	1.4M	678.7K	641.9K
Total Stockholder Equity	2.4M	4.6M	9.9M	5.1M	8.8M	5.1M
Net Tangible Assets	154.7K	2.4M	4.6M	9.9M	11.4M	11.9M
Net Debt	(1.7M)	(2.6M)	(8.5M)	(6.4M)	(9.2M)	(8.8M)
Retained Earnings	(12.2M)	(19.4M)	(33.7M)	(45.1M)	(52.9M)	(50.3M)
Accounts Payable	403.9K	129.5K	361.0K	695.0K	35.6K	33.8K
Cash	1.7M	2.6M	8.5M	6.4M	9.3M	4.7M
Non Current Assets Total	201.0K	460K	410K	33K	92.6K	87.9K
Non Currrent Assets Other	200K	50K	0.0	33K	(1.0)	(0.95)
Cash And Short Term Investments	2.5M	4.7M	10.4M	6.6M	9.3M	5.5M
Common Stock Shares Outstanding	366.6K	494.5K	893.2K	1.2M	3.4M	1.8M
Liabilities And Stockholders Equity	2.8M	5.2M	11.0M	6.8M	9.5M	5.8M
Non Current Liabilities Total	403.9K	285K	235K	250K	26.3K	25.0K
Other Stockholder Equity	14.6M	24.1M	43.6M	50.2M	61.7M	31.8M
Total Liab	440.1K	597.1K	1.1M	1.6M	705.0K	767.0K
Net Invested Capital	2.4M	4.6M	9.9M	5.1M	8.8M	5.1M
Total Current Assets	2.6M	4.8M	10.6M	6.7M	9.4M	5.6M
Accumulated Other Comprehensive Income	0.0	(15.4K)	17.6K	22.0K	27.3K	28.6K
Net Working Capital	2.2M	4.5M	9.7M	5.3M	8.7M	5.0M
Common Stock	1.0K	1.3K	2.4K	130.0	435.0	413.25
Other Current Assets	140.6K	89.8K	94.0M	88.5K	135.4K	128.6K
Capital Stock	1.0K	1.3K	2.4K	130.0	435.0	818.0

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:

How To Invest In Hoth

Details

Is Hoth Stock a good investment?

Details

What is Hoth Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.

You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Hoth Stock analysis

When running Hoth Therapeutics' price analysis, check to measure Hoth Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hoth Therapeutics is operating at the current time. Most of Hoth Therapeutics' value examination focuses on studying past and present price action to predict the probability of Hoth Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hoth Therapeutics' price. Additionally, you may evaluate how the addition of Hoth Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio

Is Hoth Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.30)

Return On Assets

(0.59)

Return On Equity

(1.13)

The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Hoth Free Cash Flow Per Share vs Capex To Depreciation Analysis

Free Cash Flow Per Share vs Capex To Depreciation

Free Cash Flow Per Share vs Capex To Depreciation Correlation Analysis

Correlation Coefficient

Free Cash Flow Per Share

Capex To Depreciation

Hoth Therapeutics fundamental ratios Correlations

Hoth Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Hoth Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Hoth Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity

Retained Earnings	- 0.99	Net Tangible Assets
Net Debt	- 0.99	Net Tangible Assets
Retained Earnings Total Equity	- 0.98	Capital Surpluse
Retained Earnings Total Equity	- 0.95	Common Stock Total Equity
Other Stockholder Equity	- 0.95	Retained Earnings
Cash	- 0.95	Net Debt